AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35622456
Drug: E2027 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (doses ranging from 5 to 1200 mg)
Trial: 35622456
Drug: E2027 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (doses planned for phase 2 study)
Trial: 35695863
Drug: Gefitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib treatment
Trial: 36444953
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen before removal of drainage tubes and a second dose at 8 p.m. on the same day.
Trial: 36444953
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment without acetaminophen (control group).
Trial: 35193648
Drug: 6% Hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Hydroxyethyl starch (HES) 130 solution (Volulyte 6%, Fresenius Kabi, Germany)
Trial: 35193648
Drug: Crystalloid solution
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solution (Ionolyte, Fresenius Kabi, Germany)
Trial: 35979057
Drug: Propofol intravenous
RxNorm normalized name: Propofol Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol intravenous anesthesia combined with press-needle therapy
Trial: 35979057
Drug: Propofol intravenous
RxNorm normalized name: Propofol Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol intravenous anesthesia
Trial: 35762946
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for insomnia (CBTi)
Trial: 33152700
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD‐MTX; 3‐8 g/m2)
Trial: 33152700
Drug: HD‐MTX-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD‐MTX-based therapy
Trial: 33152700
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous stem cell transplantation
Trial: 33152700
Drug: Whole-brain radiation
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiation therapy
Trial: 37716952
Drug: atrasentan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atrasentan 1.25 mg/day
Trial: 33472677
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) for soil-transmitted helminths (STH)
Trial: 33724256
Drug: Celecoxib augmentation
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib augmentation (n = 18)
Trial: 33724256
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 9)
Trial: 33371159
Drug: Shi-style spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shi-style spine balance manipulation combined with Daoyin therapy
Trial: 33834521
Drug: Baricitinib 4-mg
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4-mg plus TCS
Trial: 33834521
Drug: Baricitinib 2-mg
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2-mg plus TCS
Trial: 33560442
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy without rituximab
Trial: 35414092
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) consisting of eight modules focusing on psychoeducation, cognitive restructuring, pacing, and emotion regulation, with weekly written feedback from a trained therapist.
Trial: 34488326
Drug: Pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (100 mg as intravenous infusion)
Trial: 32881912
Drug: Sitagliptin (DPP4i)
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin (DPP4i) at 100mg daily for 28 days
Trial: 34812982
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 33145862
Drug: High-dose NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NSAID (piroxicam) alone
Trial: 33145862
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and high-dose NSAID combination
Trial: 33322280
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (20 g/day) and 8% maltodextrin
Trial: 34625598
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (GLAR)
Trial: 34857545
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor dapagliflozin (5 mg daily)
Trial: 33915962
Drug: Reishi Mushroom
RxNorm normalized name: REISHI MUSHROOM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reishi Mushroom (lower-dose)
Trial: 33915962
Drug: Reishi Mushroom
RxNorm normalized name: REISHI MUSHROOM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reishi Mushroom (higher-dose)
Trial: 33915962
Drug: Stinging Nettle
RxNorm normalized name: Stinging Nettle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stinging Nettle (lower-dose)
Trial: 33915962
Drug: Stinging Nettle
RxNorm normalized name: Stinging Nettle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stinging Nettle (higher-dose)
Trial: 33915962
Drug: Epimedium (lower-dose)
RxNorm normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epimedium (lower-dose)
Trial: 33915962
Drug: Epimedium (higher-dose)
RxNorm normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epimedium (higher-dose)
Trial: 34644471
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (48 international units daily)
Trial: 39260927
Drug: Evogliptin 10
RxNorm normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin 10 mg
Trial: 35833454
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg/day, titrated every 3-4 days)
Trial: 33905493
Drug: 64 mg
RxNorm normalized name: sulfur 64 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg guanabenz
Trial: 33905493
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg guanabenz
Trial: 33905493
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg guanabenz
Trial: 35488976
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (psychoeducation/supportive therapy)
Trial: 32169808
Drug: DCs vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCs vaccine (group III)
Trial: 32169808
Drug: Trans-arterial chemoembolization
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-arterial chemoembolization (TACE) and DCs as adjuvant therapy (group I)
Trial: 32169808
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment (group IV)
Trial: 33576546
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment
Trial: 33978070
Drug: Integrated approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated approach including balloon uterine stent placement, artificial cycle, intrauterine perfusion of Danshen injection, and oral Chinese medicine
Trial: 32084530
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg or 8 mg)
Trial: 32351164
Drug: Ublituximab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab (150 mg over 1–4 hours on day 1 and 450–600 mg over 1–3 hours on day 15 and week 24)
Trial: 33836810
Drug: Unaccompanied course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unaccompanied course (no support from psychologist via weekly phone calls)
Trial: 33836810
Drug: Accompanied course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accompanied course (support from a psychologist via weekly phone calls)
Trial: 36484872
Drug: Synbiotic capsule
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic capsule containing 6 × 10^9 CFU Lactobacillus coagulans SC‐208, 6 × 10^9 CFU Lactobacillus indicus HU36 and fructooligosaccharide as a prebiotic, taken twice a day for eight weeks
Trial: 36484872
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken twice a day for eight weeks
Trial: 33771102
Drug: Prenatal exercise
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal exercise (150 min of moderate‐intensity weekly exercise)
Trial: 35235774
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1,000 mg
Trial: 35341156
Drug: RG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG group (general treatments combining reduced glutathione)
Trial: 35341156
Drug: CHF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF group (general treatments combining Chuan Huang Fang)
Trial: 35341156
Drug: RG +
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG + CHF group (general treatments combining reduced glutathione and Chuan Huang Fang)
Trial: 33136134
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplements plus 200 mg of vitamin C
Trial: 33136134
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplements only
Trial: 34967656
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy in addition to conventional heart failure therapy
Trial: 34967656
Drug: Conventional heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heart failure therapy alone
Trial: 32546962
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of fimasartan 120 mg and atorvastatin 40 mg
Trial: 32546962
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of fimasartan and atorvastatin
Trial: 34180843
Drug: Presentation about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation about the futility of antibiotic treatment of URTIs
Trial: 34180843
Drug: Presentation about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation about the adverse effects associated with antibiotics
Trial: 32031887
Drug: Early integrated
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early integrated palliative and oncology care (PC), with expected monthly meetings with a PC clinician until death.
Trial: 36041655
Drug: Astegolimab 490
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 490 mg every 4 weeks for 16 weeks
Trial: 34477823
Drug: Avoid antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoid antiplatelet therapy (Control)
Trial: 34799682
Drug: D-Cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (DCS) 50 mg
Trial: 34799682
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 25 mg
Trial: 34856181
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 μg/kg) plus Albendazole (400 mg)
Trial: 34856181
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) plus Placebo
Trial: 35395204
Drug: gameChange VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gameChange VR therapy plus usual care
Trial: 34127100
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Transcranial Magnetic Stimulation (rTMS) with Ketamine (CTK)
Trial: 34774396
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) continued group
Trial: 34096500
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition during therapeutic hypothermia
Trial: 34512511
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (target SBP 130-140 mmHg)
Trial: 34512511
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (SBP <180 mmHg)
Trial: 35979609
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg UDCA for 6 months
Trial: 33976352
Drug: Carbon nanoparticle
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon nanoparticle suspension
Trial: 33601706
Drug: Next-intended antidepressant
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-intended antidepressant (AD) treatment with predicted moderate gene-drug interaction potential
Trial: 33601706
Drug: Next-intended antidepressant
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-intended antidepressant (AD) treatment with predicted clinically significant gene-drug interaction potential
Trial: 33601706
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with an antidepressant (AD) in the past two years
Trial: 35487576
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + BHB-ME (20 ± 2 g CHO and 590 mg/kg body mass β-hydroxybutyrate monoester)
Trial: 35487576
Drug: CHO (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (90 ± 9 g carbohydrate)
Trial: 34870387
Drug: Accommodating variable-resistance
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accommodating variable-resistance exercise (AVr-Ex) program, 3 sessions/week over 8 weeks, in addition to usual physical therapy
Trial: 34187220
Drug: Framing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Framing treatment benefits in terms of loss (mortality)
Trial: 32143733
Drug: Witnessed oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witnessed oral informed consent (IC) prior to randomization and written IC after percutaneous coronary intervention for ST-segment elevation myocardial infarction patients.
Trial: 32143733
Drug: Witnessed oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witnessed oral informed consent (IC) prior to randomization and written IC before angiography for non-ST-segment elevation myocardial infarction patients.
Trial: 32143733
Drug: Witnessed oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witnessed oral informed consent (IC) process.
Trial: 38178051
Drug: Sham manipulation
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham manipulation treatment
Trial: 36328372
Drug: Ornidazole 1
RxNorm normalized name: ornidazole 167 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 1 g orally 12 hours before surgery
Trial: 35766258
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention including bedside delivery of P2Y12 inhibitor, education, automated reminder calls, and outreach for refill delays.
Trial: 32338063
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DBPR108
Trial: 32338063
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DBPR108
Trial: 32338063
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DBPR108
Trial: 37290207
Drug: NEPA +
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NEPA + oral low-dose DEX (4 mg) on days 2-3 (DEX3)
Trial: 37290207
Drug: NEPA +
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NEPA + standard DEX (4 mg twice daily) on days 2-4 (DEX4)
Trial: 33896356
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg/2 mL pre-filled syringe (PFS)
Trial: 33641430
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenous tranexamic acid (TXA) diluted in 100 ml normal saline (NS)
Trial: 33641430
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo 100 ml normal saline (NS)
Trial: 32124422
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention including adapted tango, music therapy, social activities, cognitive intervention, and psycho-education for 6 months.
Trial: 33683710
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg) and Ondansetron (4 mg)
Trial: 32487507
Drug: 10 1-mg
RxNorm normalized name: cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 1-mg hydromorphone tablets or no hydromorphone if no opioids were required in hospital
Trial: 32487507
Drug: 20 1-mg
RxNorm normalized name: baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 1-mg hydromorphone tablets (standard post-cesarean opioid prescription)
Trial: 35935409
Drug: Tapered discontinuation
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapered discontinuation of antipsychotic medication
Trial: 32016928
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) - bolus dose of 10 mg/kg followed by 8 hours continuous infusion of 3 mg/kg/h
Trial: 35102364
Drug: Gastric hop
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric hop extract (500 mg, quick-release capsules)
Trial: 35102364
Drug: Duodenal hop
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal hop extract (500 mg, delayed-release capsules)
Trial: 36203149
Drug: RTS,S/AS01E malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E malaria vaccine (primary series and two seasonal boosters) and seasonal malaria chemoprevention (four monthly cycles per year)
Trial: 36203149
Drug: RTS,S/AS01E malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E malaria vaccine alone
Trial: 36203149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SMC and RTS,S/AS01E
Trial: 36240478
Drug: Rogaratinib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rogaratinib (800 mg orally twice daily, 3-week cycles)
Trial: 36240478
Drug: Chemotherapy (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (docetaxel 75 mg/m2, paclitaxel 175 mg/m2, or vinflunine 320 mg/m2 intravenously once every 3 weeks)
Trial: 36240478
Drug: Chemotherapy (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (in exploratory analysis)
Trial: 34081408
Drug: Recombinant tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tetanus vaccine (TeNT-Hc 10/20/30 µg)